<DOC>
	<DOCNO>NCT00053118</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : Phase I trial study effectiveness combine chemotherapy peripheral stem cell transplantation treat child central nervous system cancer .</brief_summary>
	<brief_title>Chemotherapy Stem Cell Transplantation Treating Children With Central Nervous System Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasibility administer outpatient protocol comprise high-dose carboplatin autologous stem cell support etoposide pediatric patient primary central nervous system malignancy . - Determine maximum tolerate dose carboplatin administer regimen patient . - Determine toxicity regimen patient . OUTLINE : This dose-escalation study carboplatin . Patients receive filgrastim ( G-CSF ) IV daily 6 day follow maximum 5 apheresis session . If target number peripheral blood stem cell achieve , patient receive G-CSF undergo apheresis 2-week rest . At least 3 day completion G-CSF , patient receive high-dose carboplatin IV 1 hour day 1 , stem cell reinfusion day 3 , G-CSF subcutaneously day 4-18 43-61 , oral etoposide 3 time daily day 21-42 . Treatment continue maximum 4 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos carboplatin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients follow monthly 1 year annually thereafter . PROJECTED ACCRUAL : A total 3-15 patient accrue study .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Retinoblastoma</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary central nervous system malignancy Recurrent , persistent , progressive disease least 1 prior firstline treatment regimen PATIENT CHARACTERISTICS : Age 18 initial diagnosis Performance status ECOG 02 Life expectancy At least 8 week Hematopoietic Absolute neutrophil count great 750/mm^3 WBC great 2,500/mm^3 Platelet count great 100,000/mm^3 No underlying myelodysplasia , stem cell disorder , inherent hematologic synthetic defect Hepatic Liver function test less 2 time normal OR Absence active hepatitis liver biopsy Bilirubin le 1.5 mg/dL Renal Glomerular filtration rate great 60 mL/min radionucleotide assay Cardiovascular Ejection fraction least 45 % Pulmonary Clinically normal pulmonary function ( patient 5 year age ) FEV_1 FVC least 50 % ( patient 5 year age ) OR Arterial blood gas normal DLCO great 50 % Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No mucositis mucosal infection HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy At least 3 week since prior systemic cytotoxic chemotherapy Endocrine therapy Not specify Radiotherapy At least 6 month since prior radiotherapy pelvis spine Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>childhood central nervous system germ cell tumor</keyword>
	<keyword>childhood choroid plexus tumor</keyword>
	<keyword>childhood craniopharyngioma</keyword>
	<keyword>childhood grade I meningioma</keyword>
	<keyword>childhood grade II meningioma</keyword>
	<keyword>childhood grade III meningioma</keyword>
	<keyword>recurrent childhood brain stem glioma</keyword>
	<keyword>recurrent childhood cerebellar astrocytoma</keyword>
	<keyword>recurrent childhood cerebral astrocytoma</keyword>
	<keyword>recurrent childhood ependymoma</keyword>
	<keyword>recurrent childhood medulloblastoma</keyword>
	<keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>recurrent retinoblastoma</keyword>
	<keyword>childhood visual pathway hypothalamic glioma</keyword>
	<keyword>childhood atypical teratoid/rhabdoid tumor</keyword>
	<keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
</DOC>